Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10401309 | 0.98 | OPRM1 (0.47) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL10506432 | 0.98 | OPRM1 (0.47) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| SCHEMBL23950835 | 0.86 | OPRM1 (0.39) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| SCHEMBL18634599 | 0.81 | L3MBTL3 (0.50) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| SCHEMBL18614904 | 0.81 | L3MBTL3 (0.50) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| SCHEMBL18614900 | 0.81 | L3MBTL3 (0.50) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| SCHEMBL5514265 | 0.80 | CYP2D6 (0.41) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| SCHEMBL2306320 | 0.79 | L3MBTL3 (0.61) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| SCHEMBL4486797 | 0.79 | ACHE (0.46) | OPRM1CYP2D6KMT2ACHRM2CHRM4 | |
| SCHEMBL2905814 | 0.79 | CYP2D6 (0.52) | OPRM1CYP2D6KMT2ACHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118853107-A | Weighting agent for drilling fluid and preparation method thereof | 古莱特科技股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | claimed |
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | claimed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | claimed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | claimed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
| US-4943641-A | 3-aminoazetidine, its salts, process for their preparation and intermediates of synthesis | SANOFI (FR) | 1990-07-24 | — | — | US | claimed |
| EP-0155870-B1 | 3-AMINOAZETIDINE, ITS SALTS, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES | SANOFI (FR) | 1989-04-26 | — | — | EP | claimed |
| US-4822895-A | 3-aminoazetidine, its salts and intermediates of synthesis | SOCIETE ANONYME - SANOFI (FR) | 1989-04-18 | — | — | US | claimed |
| EP-0155870-A1 | 3-Aminoazetidine, its salts, process for their preparation and intermediates | SANOFI (FR) | 1985-09-25 | — | — | EP | claimed |
| CN-119751326-A | Method for high-throughput synthesis of 1-phenyl azetidine compounds | 上海泓博尚奕药物技术有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119504544-A | Preparation method of N-Boc-3-amino azetidine | 宿迁晨阳医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-118853107-A | Weighting agent for drilling fluid and preparation method thereof | 古莱特科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118853107-A | Weighting agent for drilling fluid and preparation method thereof | 古莱特科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-4638067-A | NAPHTHYRIDINE AND QUINOLINE CARBOXYLIC ACIDS | WARNER-LAMBERT CO. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0155870-A1 | 3-Aminoazetidine, its salts, process for their preparation and intermediates | SANOFI (FR) | 1985-09-25 | — | — | EP | disclosed |
| EP-0153163-A2 | 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0106489-A2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | TRPV1, UTS2R, OPRL1 | OPRM1 5/4885CYP2D6 981/4885KMT2A 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.